Skip to main content

Table 1 Patients’ characteristics

From: Iodine-125 seed brachytherapy for early stage prostate cancer: a single-institution review

Age (year)   
  Mean ± SD 68.5 ± 5.6
PSA at diagnosis (ng/mL)  
  Mean ± SD 7.2 ± 2.6
  10 or less 144
  10-20 25
Clinical T stage  
  T1c 143
  T2a 16
  T2b 7
  T2c 1
  Ne 2
Gleason score   
  4-6 166
  7 2
  Ne 1
Neoadjuvant ADT  
  No 125
  Yes 42
  Ne 2
IPSS at baseline  
  Mean ± SD 6.3 ± 4.0 (*)
Follow-up period (months)  
  Mean (range) 50 (1–85 months)
  1. SD: Standard deviation, Ne: Not evaluated.
  2. ADT: Androgen deprivation therapy.
  3. IPSS: International prostate symptom score.
  4. (*) 162 patients included.